Ecteinascidin 743 in Treating Children With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

January 31, 2005

Study Completion Date

September 30, 2005

Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

ECTEINASCIDIN 743

Trial Locations (47)

3052

Royal Children's Hospital, Parkville

6001

Princess Margaret Hospital for Children, Perth

10021

Memorial Sloan-Kettering Cancer Center, New York

10032

Columbia Presbyterian Hospital, New York

13210

State University of New York - Upstate Medical University, Syracuse

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

21231

Johns Hopkins Oncology Center, Baltimore

27710

Duke Comprehensive Cancer Center, Durham

30322

Emory University Hospital - Atlanta, Atlanta

48109

Mott Children's Hospital, Ann Arbor

48201

Children's Hospital of Michigan, Detroit

53226

Midwest Children's Cancer Center, Milwaukee

55905

Mayo Clinic Cancer Center, Rochester

60614

Children's Memorial Hospital, Chicago, Chicago

63104

Cardinal Glennon Children's Hospital, St Louis

64108

Children's Mercy Hospital, Kansas City

72205

University of Arkansas for Medical Sciences, Little Rock

76104

Cook Children's Medical Center - Fort Worth, Fort Worth

77030

Baylor College of Medicine, Houston

84132

Huntsman Cancer Institute, Salt Lake City

91010

Beckman Research Institute, City of Hope, Los Angeles

92868

Children's Hospital of Orange County, Orange

94304

Lucile Packard Children's Hospital at Stanford, Palo Alto

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

92093-0658

University of California San Diego Cancer Center, La Jolla

90027-0700

Children's Hospital Los Angeles, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

32610-100277

Shands Hospital and Clinics, University of Florida, Gainesville

46202-5265

Indiana University Cancer Center, Indianapolis

02111

Boston Floating Hospital Infants and Children, Boston

02115

Dana-Farber Cancer Institute, Boston

39216-4505

University of Mississippi Medical Center, Jackson

07601

Hackensack University Medical Center, Hackensack

14263-0001

Roswell Park Cancer Institute, Buffalo

45229-3039

Children's Hospital Medical Center - Cincinnati, Cincinnati

29425-0721

Medical University of South Carolina, Charleston

38105-2794

Saint Jude Children's Research Hospital, Memphis

37232-6838

Vanderbilt Cancer Center, Nashville

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

53792-0001

University of Wisconsin Hospital and Clinics, Madison

M5G 1X8

Hospital for Sick Children, Toronto

H3H 1P3

Montreal Children's Hospital, Montreal

H3T 1C5

Hopital Sainte Justine, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00006463 - Ecteinascidin 743 in Treating Children With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter